Retatrutide led to dose-dependent reductions in body weight of up to 24.2% at 48 weeks, with a safety profile comparable to other GLP-1-based therapies. Jastreboff et al., NEJM Secondary Benefits Improved HbA1c in both diabetic and pre-diabetic participants Significant reductions in liver fat (a marker for NAFLD/NASH reversal) Lowered triglycerides, LDL, and inflammatory markers Favorable impact on blood pressure and fasting insulin levels Tolerability and Safety Most side effects were GI-related and dose-dependent : Nausea Constipation Occasional vomiting All were similar in frequency and severity to those seen in Semaglutide trials No serious adverse events were reported Dropout rates were low across all dose groups These results suggest Retatrutide may offer not only more dramatic weight loss , but also better metabolic improvements and potential muscle-sparing advantages making it a standout candidate for both medical and performance-focused applications
3 Discussion APL presents with severe clinical manifestations, with high risks of bleeding and embolism during onset and induction therapy, potentially leading to fatal outcomes
This is not necessarily a negative side effect but rather an indication of accelerated cell turnover, where underlying congestion is brought to the surface as the skin rapidly sheds old cells and regenerates new ones
Research shows that diarrhea is reported in both clinical trials and real-world use of semaglutide
First things first: your body needs nutrients to heal itself and perform the bazillion functions it needs to perform every day
)
